All News

RheumNow Podcast square

UBER Rheumatology Ride (3.6.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

The Role of Calcineurin Inhibitors in Lupus Nephritis

Urvi Zala, MD

In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus, contributing significantly to the morbidity and mortality of the affected individuals. However, significant differences in clinical approaches to lupus nephritis management still persist.

Read Article
CART

B cell Targeted CAR-T Therapy for Autoimmune Diseases

EurekAlert!

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with unprecedented specificity.

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Hydroxychloroquine Lowers SLE and RA Hospitalizations

Jack Cush, MD

A population based study from British Columbia, Canada, shows that antimalarial adherence was associated with a lower risk of hospital admission in patients with rheumatoid arthritis

Read Article
RheumNow Podcast square

SATISFACTION (2.27.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
eyedrops.jpg (keep)

Epidemiology of Dry Eye Autoimmune Disease

Jack Cush, MD

Dry eye rates upwards of 20% were seen across nine common autoimmune diseases other than Sjögren's, most often in rheumatoid arthritis (39.3%) with Crohn's disease bringing up the rear (23.0%), according to Chi-Chin Sun, MD, PhD, of Chang Gung Memorial Hospital in Keelung, Taiwan, and colleagues.

Read Article
infused.jpg

Early vs Delayed Belimumab in Lupus

Jack Cush, MD

An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost effectiveness and clinical utility of early BEL initiation in active lupus patients.

Read Article
RheumNow Podcast square

Referral Rules to Live By (2.20.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Highlights include referral rules, combination biiologics in psoriasis and don't use JAK inhibitors in pregnancy.

Read Article
Olsen RNL26

Prevention in Lupus and Therapeutic Evolution in Sjögren’s

Audrey Gibson, PA-C

The notion of intervening in autoimmune disease prior to the onset of irreversible tissue damage has evolved beyond a theoretical framework; it is presently undergoing empirical evaluation. Recent discussions on incomplete lupus and the SMILE trial, alongside advances in Sjögren’s therapeutics, highlight both the promise and complexity of prevention and precision treatment in systemic autoimmunity.

Read Article
Hydroxychloroquine Lowers SLE and RA Hospitalizations A population-based study from British Columbia, Canada, shows that antimalarial adherence was associated with a lower risk of hospital admission in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus https://t.co/YR8Zfw8pL6
Dr. John Cush RheumNow ( View Tweet)
FDA has granted Fast Track designation to J&Js nipocalimab for use in #SLE based on the results of a Phase 2b JASMINE study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing https://t.co/puQN6ecScj https://t.co/au422eamLR

Links:

Dr. John Cush RheumNow ( View Tweet)
Observational study of 42 Mexican lupus nephritis pts on Immunosuppressives + Calcineurin Inhibitors (CNIs) @ 12 mos complete & partial responses seen in 26% & 36%, w/ signif reduction in proteinuria (2.89 vs 0.72 g/d, p < .001), & transient decrease in eGFR at 12 mo (109 vs 114) https://t.co/G70POtJwhS
Dr. John Cush RheumNow ( View Tweet)
CDC study of Death certificate data showed that btw 2018–2023, there were 14,936 #SLE deaths (43% w/ SLE as the underlying cause). Mortality rate per million: females 5.97 > males 1.16, blacks 10.7. Causes of death:heart disease (0.93), cancer (0.56), COVID-19 (0.51). https://t.co/qTe6O66wRO
Dr. John Cush RheumNow ( View Tweet)
The prevalence of Systemic lupus erythematosus (SLE) in Australia is 26,788 (16,294 certain, 10,494 uncertain cases). Betw 2010-2022 incidence was 77-127/100,000 (certain cases). About half had received SLE care in an outpatient setting. Australia is 1/13 the population of USA https://t.co/n1sbFNPRbn
Dr. John Cush RheumNow ( View Tweet)
Early vs Delayed Belimumab in Lupus An economic evaluation of early vs delayed use of the Blys inhibitor, belimumab (BEL), in systemic lupus erythematosus (SLE) has shown both cost-effectiveness and clinical utility of early BEL initiation in active lupus patients. https://t.co/7unHZhR6Dd
Dr. John Cush RheumNow ( View Tweet)
What did you miss at RheumNow Live 2026? Our Poster Hall features new data across: • Psoriatic Arthritis • Systemic Lupus Erythematosus • Lupus Nephritis • Vasculitis • Polymyalgia Rheumatica • Axial Spondyloarthritis From Phase III trials to real-world evidence, these https://t.co/nuXGUdmwon
Dr. John Cush RheumNow ( View Tweet)
Prevention in Lupus and Therapeutic Evolution in Sjögren’s explores the proactive approach in autoimmune diseases, moving from theory to empirical evaluation. Recent discussions on incomplete lupus and the SMILE trial, along with advancements in Sjögren’s treatments, underscore https://t.co/KY9nHnpkxk
Dr. John Cush RheumNow ( View Tweet)
What did you miss at RheumNow Live 2026? Our Poster Hall features new data across: • Psoriatic Arthritis • Systemic Lupus Erythematosus • Lupus Nephritis • Vasculitis • Polymyalgia Rheumatica • Axial Spondyloarthritis From Phase III trials to real-world evidence, these

Dr. John Cush RheumNow ( View Tweet)

Genentech announced results of Phase III, MAJESTY OL study of obinutuzumab vs tacrolimus in 142 pts w/ primary membranous nephropathy & found signif more complete remissions at 2 yrs in obintuzumab Rx pts. Obintuzumab (Gazyva) if FDA approved for lupus nephritis. https://t.co/maJbvUCkBe
Dr. John Cush RheumNow ( View Tweet)
RT @ericdeinMD #RNL26 Arthroplasty risks in RMD AxSpA - Respiratory complications (OR 1.7), PNA (2.2) SLE - complications ass w/ severity/activity. Renal failure, PE, sepsis, stroke, mortality depending on activity PsA - complications related to co-morbidities, not PsA https://t.co/jr0hwh3CPe
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×